Onconetix (NASDAQ:ONCO – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($76.01) earnings per share for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.02 million. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%.
Onconetix Price Performance
ONCO stock traded down $0.30 during trading hours on Monday, reaching $2.91. The stock had a trading volume of 62,174 shares, compared to its average volume of 167,959. The stock has a market capitalization of $1.72 million, a PE ratio of 0.00 and a beta of 2.62. The stock has a 50-day simple moving average of $6.24 and a 200 day simple moving average of $110.32. Onconetix has a fifty-two week low of $2.76 and a fifty-two week high of $1,610.00.
Wall Street Analyst Weigh In
Several analysts recently issued reports on ONCO shares. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Wall Street Zen raised Onconetix from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Read Our Latest Report on Onconetix
Onconetix Company Profile
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Read More
- Five stocks we like better than Onconetix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
